Company
Catalent, Inc.
Headquarters: Somerset, NJ, United States
Founded: 2007
Employees: 17,300
CEO: Mr. John R. Chiminski
Market Cap
$7.85 Billion
USD as of Jan. 1, 2024
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Catalent, Inc. has the following listings and related stock indices.
Stock: NYSE: CTLT wb_incandescent
Stock: FSX: 0C8 wb_incandescent
Product & Services
Drug pre-formulation, formulation, analytical testing, clinical and commercial manufacturing, clinical packaging and supply chain, regulatory consulting
Key People
John Chiminski (Chair, CEO), Alessandro Maselli (President, COO), Thomas Castellano (Senior Vice President, CFO)
Financials
Revenue: US$3.998 Billion (Fiscal Year Ended June 30, 2021)
Operating income: US$0.828 Billion (Fiscal Year Ended June 30, 2021)
Net income: US$0.585 Billion (Fiscal Year Ended June 30, 2021)
Total assets: US$9.112 Billion (Fiscal Year Ended June 30, 2021)
Total equity: US$3.915 Billion (Fiscal Year Ended June 30, 2021)